TRUSTED SAFETY PROFILE
Most Frequent† Adverse Events in 2 Studies of ILEVRO® (nepafenac ophthalmic suspension) 0.3%1,2
According to the Prescribing Information, the most frequently reported ocular adverse reactions following cataract surgery occurring in approximately 5% to 10% of patients were capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, and sticky sensation.1
According to the Prescribing Information, the most frequently reported ocular adverse reactions following cataract surgery occurring in approximately 5% to 10% of patients were capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, and sticky sensation.1
Adverse Event | ILEVRO® (n=1339) | Vehicle (n=455) |
|---|---|---|
| Headache | 2.0% | 1.1% |
| Intraocular pressure increase | 1.1% | 0.2% |
| Injury | 0.7% | 0.7% |
| Posterior capsule rupture | 0.6% | 0.2% |
| Corneal edema | 0.4% | 1.3% |
| Cystoid macular edema | 0.3% | 0.7% |
| Cataract operation complication | 0.2% | 0.7% |
| Iritis | 0.1% | 0.7% |
Adverse Event | ILEVRO® (n=1339) |
|---|---|
| Headache | 2.0% |
| Intraocular pressure increase | 1.1% |
| Injury | 0.7% |
| Posterior capsule rupture | 0.6% |
| Corneal edema | 0.4% |
| Cystoid macular edema | 0.3% |
| Cataract operation complication | 0.2% |
| Iritis | 0.1% |
Adverse Event | Vehicle (n=455) |
|---|---|
| Headache | 1.1% |
| Intraocular pressure increase | 0.2% |
| Injury | 0.7% |
| Posterior capsule rupture | 0.2% |
| Corneal edema | 1.3% |
| Cystoid macular edema | 0.7% |
| Cataract operation complication | 0.7% |
| Iritis | 0.7% |
Data provided through MMIT and are current as of 2/2024. The information provided in this website is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Nothing herein may be construed as an endorsement, approval, recommendation, representation or warranty of any kind by any plan or insurer referenced herein.
All treatment-emergent adverse events reported in 2 clinical trials of ILEVRO® and occurring at an incidence of ≥0.5% in either group.
Designed for potency and penetration1
Stay connected
with us
References: 1. Modi SS, Lehmann RP, Walters TR, et al. Once-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: phase 3 study. J Cataract Refract Surg. 2014;40(2):203-211. 2. ILEVRO (nepafenac ophthalmic suspension) 0.3% [package insert]. Harrow IP, LLC; 2023.